Portorn Biopharm aims to manufacture new class of IBD medication using gut bacteria spores

Chain Biotechnology company, Porton Biopharma and Scitech have acquired grant funding from Innovate UK to investigate the manufacture of a new class of medicines that target a range of clinical conditions such as ulcerative colitis and Chrohn’s disease through interaction with the human microbiome Three leading British biotechnologies have obtained grant funding from Innovate UK

Continue Reading